亚洲房颤患者超说明书低剂量DOAC的疗效与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入20项观察性研究,比较亚洲房颤患者超说明书低剂量DOAC与标签剂量或华法林的有效性与安全性。结果显示,超说明书低剂量DOAC较标签剂量增加缺血性卒中或系统性栓塞及颅内出血风险,尤其利伐沙班;较华法林则降低大出血、消化道出血、颅内出血及全因死亡风险,但ISSE风险相似。
要点
- 超说明书低剂量DOAC较标签剂量增加ISSE(pHR=1.17)和ICH(pHR=1.27)风险。
- 利伐沙班超说明书低剂量较标签剂量显著增加ISSE风险(pHR=1.49)。
- 超说明书低剂量DOAC较华法林降低MB、GIB、ICH及全因死亡风险,ISSE风险相似。
核心结论
- 超说明书低剂量DOAC(尤其利伐沙班)较标签剂量增加ISSE风险且未降低出血,应强调遵循适当DOAC剂量。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Cochrane library和ClinicalTrials.gov(2010年至2024年7月5日),纳入20项观察性研究。
- 17项研究比较超说明书低剂量DOAC与标签剂量DOAC,5项研究比较超说明书低剂量DOAC与华法林。
- 主要结局为ISSE和MB,次要结局包括全因死亡、GIB、ICH和MI,采用随机效应模型合并HR及95%CI。
主要发现
- 超说明书低剂量DOAC较标签剂量与更高的ISSE风险相关(pHR=1.17;95%CI:1.00-1.38,p=0.048)。
- 超说明书低剂量DOAC较标签剂量与更高的ICH风险相关(pHR=1.27;95%CI:1.06-1.52,p=0.010)。
- 亚组分析显示利伐沙班超说明书低剂量较标签剂量增加ISSE风险(pHR=1.49;95%CI:1.07-2.08)。
- 超说明书低剂量DOAC较华法林降低MB风险(pHR=0.46;95%CI:0.32-0.65,p<0.001)、GIB风险(pHR=0.52;95%CI:0.29-0.93,p=0.028)、ICH风险(pHR=0.60;95%CI:0.42-0.86,p=0.005)及全因死亡风险(pHR=0.70;95%CI:0.56-0.87,p=0.001)。
- 超说明书低剂量DOAC与华法林相比ISSE风险相似。
临床怎么用
- 临床应避免无依据的超说明书低剂量DOAC,尤其利伐沙班,以降低ISSE风险。
- 对亚洲房颤患者,应依据标签推荐选择DOAC剂量,定期评估剂量适当性。
局限性
- 纳入研究均为观察性研究,可能存在混杂偏倚。
- 仅纳入亚洲房颤患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Off-label underdosed direct oral anticoagulants (DOACs) are commonly utilised in Asian patients with atrial fibrillation (AF) since they are prone to bleeding with OACs. However, the efficacy and safety of off-label underdosing DOACs are controversial. This study aimed to compare the effectiveness and safety of off-label underdosed DOACs in Asian patients with AF. METHODS: PubMed, Embase, Cochrane library, and ClinicalTrials.gov were searched from 2010 to July 5, 2024, for randomised controlled trials or observational studies that compared off-label DOACs and on-label/warfarin in Asian patients with AF. The primary outcomes included ischaemic stroke or systemic embolism (ISSE) and major bleeding (MB), while secondary outcomes included all-cause death, gastrointestinal bleeding (GIB), intracranial haemorrhage (ICH), and myocardial infarction (MI). Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Twenty observational studies were included. Seventeen studies compared off-label underdosed DOACs versus on-label DOACs, whereas five studies compared off-label underdosed DOACs versus warfarin. Off-label underdosed DOACs were associated with higher risk of ISSE (pooled HR [pHR] = 1.17; 95% CI: 1.00-1.38, p = 0.048) and ICH (pHR = 1.27; 95% CI: 1.06-1.52, p = 0.010) versus on-label. Subgroup analysis demonstrated increased ISSE risk with off-label underdosed rivaroxaban compared to on-label (pHR = 1.49; 95% CI: 1.07-2.08). Compared to warfarin, off-label underdosed DOACs were associated with decreased risk of MB (pHR = 0.46; 95% CI: 0.32-0.65, p < 0.001), GIB (pHR = 0.52; 95% CI: 0.29-0.93, p = 0.028), ICH (pHR = 0.60; 95% CI: 0.42-0.86, p = 0.005), and all-cause death (pHR = 0.70; 95% CI: 0.56-0.87, p = 0.001), while illustrating similar ISSE risk. CONCLUSIONS: Off-label underdosed DOACs, particularly rivaroxaban, was associated with increased ISSE risk but did not decrease bleeding compared to on-label. Adherence to appropriate DOAC doses should be emphasised to achieve the best clinical outcomes for Asian patients with AF.
引用
- Mongkhon P, Singkham N, Ponok K, et al. Comparative Effectiveness and Safety of Off-Label Underdosed Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis. Drug Saf. 2024. PMID: 39214955. doi:10.1007/s40264-024-01476-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。